Recently, the 67th Annual Meeting of ASTRO (the American Society for Radiation Oncology), the world’s largest and most influential academic gathering in radiation oncology, was held in San Francisco, drawing over 10,000 top radiotherapy experts and scholars globally. At the meeting, Baheal Pharma’s (stock code: 301015.SZ) portfolio company — pioneering radiosurgery company ZAP Surgical — debuted its leading brain tumor stereotactic radiotherapy robot, the ZAP-X® Gyroscopic Radiosurgery™ Platform. The company showcased the platform’s latest clinical breakthroughs and clinical data.

On September 12, 2025, Qingdao Baheal Pharma Co., Ltd. (Stock Code: 301015.SZ) entered into a strategic collaboration with Tianjin JiKun Medicine Technology Co., Ltd. As part of this agreement, Baheal will acquire a 24% stake in JiKun Medicine, securing full rights to its Class I innovative drug for pulmonary fibrosis. In addition, Baheal gains the right of first refusal—under equivalent terms—on the global compound rights of all JiKun pipeline assets.

Recently, BrioHealth Solutions, Inc., a wholly-owned subsidiary of BrioHealth in the United States, announced that its independently developed fully magnetic levitation left ventricular assist device, BrioVAD, has formally received approval from FDA to advance to the Pivotal Phase of its clinical trial following the successful completion of the Safety Phase of the INNOVATE clinical trial in the United States. The FDA has approved expanding the clinical research centers to 60 sites, with a cumulative enrollment of up to 780 subjects (including those enrolled during the Safety Phase).

On May 16, 2025, Qingdao Baheal Pharma Co., Ltd, a subsidiary of Baheal Pharma under Baheal Medical (301015.SZ), held a relocation ceremony to celebrate its Phase III construction project. Mr. Zhu Xiaowei, Director of Baheal Pharma Group, Vice President of Baheal Medical and Chairman of Baheal Pharma, Mr. Hao Yu, Vice President of Baheal Pharma Group's Campus Operation, Ms. Zheng Aiju, General Manager of Qingdao Baheal Pharma, and other leaders and guests, as well as colleagues of Qingdao Baheal Pharma, were present at the ceremony to witness this important moment together.

On April 18, 2025, the highly anticipated “China Venture Annual Awards 2024” was officially released. Thanks to the firm’s strategic foresight in backing medical original innovations and its growing influence in early-stage life science investments, Baheal Pharma Group’s investment vehicle—BAHEAL ZHONGXIN CAPITAL—secured a place in the “2024 China Top 50 Corporate Direct‐Investment Funds”, underscoring its professional strength and industry influence in the early-stage life-health investment area.